ReviewFrontiers in oncology2025
The role of gut microbiome in colorectal cancer development: a comprehensive analysis based on metabolomics and immunomodulatory mechanisms.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With shifts in lifestyle and dietary habits, the incidence of colorectal cancer has been rising annually, with an increasing prevalence among younger populations, thereby imposing a significant burden on global health. Although the rate of early diagnosis for colorectal cancer has improved due to the widespread use of gastrointestinal endoscopy, many patients still do not experience substantial improvements in survival rates or quality of life. Consequently, there is a pressing need for further in-depth research into the pathogenesis of colorectal cancer, as well as the exploration of potential methods for early diagnosis and precise treatment. As research into the gut microbiome system advances, its remarkable efficacy in the early diagnosis, treatment, and prognosis assessment of various diseases has garnered considerable attention. Variations in the gut microbiome among individuals may result in differential immune responses to specific pathogens or treatment modalities. This article reviews the interaction mechanisms between gut microbiota and immune cells in colorectal cancer, integrating the latest research findings in the field, with the aim of providing potential directions and theoretical foundations for the development of personalized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.